221 related articles for article (PubMed ID: 37298997)
1. Design, Synthesis, and Biological Evaluation of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase for the Efficient Treatment of Cancer.
Shao J; Huang L; Lai W; Zou Y; Zhu Q
Molecules; 2023 Jun; 28(11):. PubMed ID: 37298997
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Thieno[3,2-d]pyrimidine derivatives as potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) kinase.
Duan Y; Cheng H; Zhuang L; Xia J; Xu Y; Zhang R; Sun R; Lu T; Chen Y
Eur J Med Chem; 2023 Jul; 255():115370. PubMed ID: 37130473
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a potent and highly selective inhibitor of ataxia telangiectasia mutated and Rad3-Related (ATR) kinase: Structural activity relationship and antitumor activity both in vitro and in vivo.
Bin H; Chen P; Wu M; Wang F; Lin G; Pan S; Liu J; Mu B; Nan J; Huang Q; Li L; Yang S
Eur J Med Chem; 2022 Mar; 232():114187. PubMed ID: 35183872
[TBL] [Abstract][Full Text] [Related]
4. Discovery of the first ataxia telangiectasia and Rad3-related (ATR) degraders for cancer treatment.
Huang L; Shao J; Lai W; Gu H; Yang J; Shi S; Wufoyrwoth S; Song Z; Zou Y; Xu Y; Zhu Q
Eur J Med Chem; 2024 Mar; 267():116159. PubMed ID: 38325007
[TBL] [Abstract][Full Text] [Related]
5. Recent Advances in Synergistic Antitumor Effects Exploited from the Inhibition of Ataxia Telangiectasia and RAD3-Related Protein Kinase (ATR).
Wang LW; Jiang S; Yuan YH; Duan J; Mao ND; Hui Z; Bai R; Xie T; Ye XY
Molecules; 2022 Apr; 27(8):. PubMed ID: 35458687
[TBL] [Abstract][Full Text] [Related]
6. Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents.
Cui Y; Palii SS; Innes CL; Paules RS
Cell Cycle; 2014; 13(22):3541-50. PubMed ID: 25483091
[TBL] [Abstract][Full Text] [Related]
7. The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma.
Shi Q; Shen LY; Dong B; Fu H; Kang XZ; Yang YB; Dai L; Yan WP; Xiong HC; Liang Z; Chen KN
Cancer Lett; 2018 Sep; 432():56-68. PubMed ID: 29890208
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and biological characterization of proteolysis targeting chimera (PROTACs) for the ataxia telangiectasia and RAD3-related (ATR) kinase.
Alfayomy AM; Ashry R; Kansy AG; Sarnow AC; Erdmann F; Schmidt M; Krämer OH; Sippl W
Eur J Med Chem; 2024 Mar; 267():116167. PubMed ID: 38308949
[TBL] [Abstract][Full Text] [Related]
9. Ataxia-telangiectasia mutated and ataxia telangiectasia and Rad3-related kinases as therapeutic targets and stratification indicators for prostate cancer.
Gulliver C; Hoffmann R; Baillie GS
Int J Biochem Cell Biol; 2022 Jun; 147():106230. PubMed ID: 35609768
[TBL] [Abstract][Full Text] [Related]
10. The antiproliferative effects of ataxia-telangiectasia mutated and ATM- and Rad3-related inhibitions and their enhancements with the cytotoxicity of DNA damaging agents in cholangiocarcinoma cells.
Moolmuang B; Ruchirawat M
J Pharm Pharmacol; 2021 Mar; 73(1):40-51. PubMed ID: 33791808
[TBL] [Abstract][Full Text] [Related]
11. Ataxia-Telangiectasia and RAD3-Related and Ataxia-Telangiectasia-Mutated Proteins in Epithelial Ovarian Carcinoma: Their Expression and Clinical Significance.
Lee B; Lee HJ; Cho HY; Suh DH; Kim K; No JH; Kim H; Kim YB
Anticancer Res; 2015 Jul; 35(7):3909-16. PubMed ID: 26124337
[TBL] [Abstract][Full Text] [Related]
12. First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors.
Yap TA; Tan DSP; Terbuch A; Caldwell R; Guo C; Goh BC; Heong V; Haris NRM; Bashir S; Drew Y; Hong DS; Meric-Bernstam F; Wilkinson G; Hreiki J; Wengner AM; Bladt F; Schlicker A; Ludwig M; Zhou Y; Liu L; Bordia S; Plummer R; Lagkadinou E; de Bono JS
Cancer Discov; 2021 Jan; 11(1):80-91. PubMed ID: 32988960
[TBL] [Abstract][Full Text] [Related]
13. Small Molecules Targeting Ataxia Telangiectasia and Rad3-Related (ATR) Kinase: An Emerging way to Enhance Existing Cancer Therapy.
Andrs M; Korabecny J; Nepovimova E; Jun D; Hodny Z; Kuca K
Curr Cancer Drug Targets; 2016; 16(3):200-8. PubMed ID: 26882028
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer.
Nam AR; Jin MH; Park JE; Bang JH; Oh DY; Bang YJ
Cancer Res Treat; 2019 Jul; 51(3):1167-1179. PubMed ID: 30514066
[TBL] [Abstract][Full Text] [Related]
15. Ataxia Telangiectasia and Rad3-Related Activation by DNA Damage Mitigates Maladaptive Repair after Acute Kidney Injury.
Bonventre JV
Nephron; 2022; 146(3):274-277. PubMed ID: 34649246
[TBL] [Abstract][Full Text] [Related]
16. Targeting ATR Pathway in Solid Tumors: Evidence of Improving Therapeutic Outcomes.
Mavroeidi D; Georganta A; Panagiotou E; Syrigos K; Souliotis VL
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38474014
[TBL] [Abstract][Full Text] [Related]
17. Investigation of switch from ATM to ATR signaling at the sites of DNA damage induced by low and high LET radiation.
Saha J; Wang M; Cucinotta FA
DNA Repair (Amst); 2013 Dec; 12(12):1143-51. PubMed ID: 24238855
[TBL] [Abstract][Full Text] [Related]
18. Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase Inhibitor.
Knegtel R; Charrier JD; Durrant S; Davis C; O'Donnell M; Storck P; MacCormick S; Kay D; Pinder J; Virani A; Twin H; Griffiths M; Reaper P; Littlewood P; Young S; Golec J; Pollard J
J Med Chem; 2019 Jun; 62(11):5547-5561. PubMed ID: 31074988
[TBL] [Abstract][Full Text] [Related]
19. The development of ataxia telangiectasia mutated kinase inhibitors.
Andrs M; Korabecny J; Nepovimova E; Jun D; Hodny Z; Moravcova S; Hanzlikova H; Kuca K
Mini Rev Med Chem; 2014; 14(10):805-11. PubMed ID: 25138084
[TBL] [Abstract][Full Text] [Related]
20. Targeting ATR in Cancer Medicine.
Salguero C; Valladolid C; Robinson HMR; Smith GCM; Yap TA
Cancer Treat Res; 2023; 186():239-283. PubMed ID: 37978140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]